Krystal Biotech awarded director Sutherland Everett Rand 1,658 derivative securities in two transactions dated 2026-09-14, each priced at $0 per share. The code A classification identifies the entries as awards or grants, helping investors distinguish the reported transaction from an open-market purchase.

Key Highlights

  • The award was divided across two separate transactions.
  • Each transaction carried a price of $0 per share.
  • Transaction code A identifies the entries as awards or grants.

Krystal Biotech, Inc. (NASDAQ: KRYS) awarded director Sutherland Everett Rand 1,658 derivative securities across two transactions, with both entries dated 14 September 2026. Each transaction was priced at $0 per share. The records use transaction code A.

Director Award Covers 1,658 Derivative Securities

Rand’s award was recorded through two separate transactions rather than a single entry, while the combined number of derivative securities was 1,658. The transaction date attached to both entries was 14 September 2026, keeping the award within one reported date. The price assigned to each transaction was $0 per share. That amount applies to the derivative securities covered by the entries and does not represent a separate figure for the overall award. Transaction code A identifies an award or grant under the transaction coding convention used for these records. The code therefore describes the nature of both entries as awards or grants. Rand is identified as a director of Krystal Biotech, Inc. and the securities involved are derivative securities of the company. Transaction code A denotes an award, grant, or other Acquisition from the company.